The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Application of artificial intelligence to predict a new class of novel synthetic lethal targets.
 
Spyro Mousses
Employment - Systems Oncology
Leadership - Systems Imagination; Systems Oncology
Stock and Other Ownership Interests - Systems Imagination; Systems Oncology
Consulting or Advisory Role - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Patents held by employer, Systems Oncology
 
David Schneider
Patents, Royalties, Other Intellectual Property - Patents for technologies based on sequencing to be used in novel ways. Assignment to company (Systems Imagination). (Inst)
 
Jeff Kiefer
Employment - Systems Oncology; Systems Oncology
Consulting or Advisory Role - Systems Imagination
 
Pieter Derdeyn
No Relationships to Disclose
 
Kendyl Douglas
No Relationships to Disclose
 
Abhishek Kothari
No Relationships to Disclose
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Anthem Inc; Capella Therapeutics; Cell Therapeutics; CerRx; McKesson; Medtronic; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Consulting or Advisory Role - 2X Oncology; 7 Hills Pharma; AADi; Actinium Pharmaceuticals; Adicet Bio; Aduro Biotech; Aeglea Biotherapeutics; Agenus; AiMed; Alpha Cancer Technologies; Aptose Biosciences; Araxes Pharma; ARIAD; ARMO BioSciences; Arvinas; Athenex; Bellicum Pharmaceuticals; BiolineRx; Biospecifics Technologies; BioXCel therapeutics; Boston Biomedical; Boston Scientific; Bryologyx; CanBas; Cancer Prevention Pharmaceuticals; Celgene; Codiak Biosciences; Corcept Therapeutics; CORRONA; CV6 Therapeutics; CytomX Therapeutics; Decoy Biosystems; Defined Health; DNAtrix; EMD Serono; Erimos Pharmaceuticals; Esperance Pharmaceuticals; Evelo Therapeutics; Fate Therapeutics; FibroGen; Five Prime Therapeutics; FORMA Therapeutics; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gimbal; Globe Life Science; Helix BioPharma; Histogen; Horizon Discovery; HUYA Bioscience International; Imaging Endpoints; Immodulon Therapeutics; Immunophotonics; Innate Pharma; Innokeys; Intezyne Technologies; Ipsen; Jounce Therapeutics; Kalos Therapeutics; Kelun; Kura Oncology; L.E.A.F. Pharmaceuticals; Lixte Biotechnology; Medical Prognosis Institute; miRNA Therapeutics; Novita Pharmaceuticals; Novocure; Nucana; Oncology Venture; Oncolyze; OSI Pharmaceuticals; Phosplatin Therapeutics; RadImmune; Reflexion Medical; RenovoRx; Riptide Bioscience; Samumed; Samus Therapeutics; SciClone; Senhwa Biosciences; Sirnaomics; SOBI; SOTIO; Strategia Therapeutics; Sumitomo Dainippon; Sun Biopharma; Synergene; Systems Imagination; TargaGenix; TD2; Tolero Pharmaceuticals; TP Therapeutics; Trans Med; Trovagene; Veana Therapeutics; Verily; Vicus Therapeutics
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
 
Chris Yoo
Leadership - Systems Oncology
Stock and Other Ownership Interests - Systems Oncology
Consulting or Advisory Role - Systems Oncology
Patents, Royalties, Other Intellectual Property - Systems Imagination, Inc. (Inst)